What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Velocity Clinical Research

Home
United States
Durham, NC
Velocity Clinical Research

Velocity is the world's leading integrated site organization.

08/22/2025

Heading to Orlando for the SCRS Global Site Solutions Summit? Discover how Velocity is accelerating research programs for Sponsors and improving the clinical trial experience for participants.

At this event:
• Paul Evans
• Sara Smiley, DO, FACP
• Craig Koch
• Jenn Carl
• Dan Robitaille
• Paul Kergides
• Grant Miller

Connect with our team before the show and visit us at booth 219!

08/21/2025

In 2025, clinical trials supported by Velocity contributed to the FDA approval of 10 new products, as well as two updated product approvals.

Since the start of 2024, our sites have supported research for 20 products that earned U.S. FDA approval. In total, Velocity sites have played a role in the development of 75 approved treatments and vaccines.

Patient centricity is about more than improving the trial experience. When we can deliver high-quality data at scale, life-changing therapies can reach the market faster.

08/20/2025

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism.

The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential as a meaningful oral treatment option for people living with T2D.

Congratulations to our Dallas site and the entire research team for their contributions to this important work.

Read the full article: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70022

08/18/2025

Congratulations to two of our U.K. sites for recently achieving FPI for two trials!

Our High Wycombe site randomized the first patient in a global chronic kidney disease trial. The site was greenlit and screened its first participant within about two weeks of contract ex*****on. Well done to Judith Mackay, MBBS, PhD, MRCP, and team!

Earlier this year, our North London site became the first in the U.K. to screen and randomize a patient in a chronic spontaneous urticaria trial. Congratulations to Kamran Hussain, MBBS, and team on this achievement!

08/14/2025

AI is everywhere—but in clinical trials, it can’t just be everywhere. At Velocity, we’ve built a rigorous AI governance framework to ensure that every model we use is not only powerful, but also trustworthy, secure, and compliant.

We evaluated leading frameworks from across the industry—including Gartner’s AI TRiSM and Microsoft’s Responsible AI principles—to create a model that fits the unique demands of clinical research. The result? A system that helps us decide which AI tools are fit for purpose—and which ones aren’t.

From vendor tools to in-house models like VISION, every AI system at Velocity must pass our TRiSM-based assessment before it’s approved for use. Because in our world, efficiency can’t come at the cost of ethics, safety, or patient trust.

Read the full article to learn how we’re making AI work responsibly in clinical trials: https://velocityclinical.com/not-all-ai-belongs-in-clinical-trials-heres-how-we-decide-which-models-do/

07/31/2025

William Cromwell, MD, FAHA, FNLA, shares his perspective on how targeted treatments are reshaping cardiometabolic research, and why now is an ideal moment to leverage expertise at scale.

As a leader of the Cardiometabolic CARE Council, and Principal Investigator at our site in Durham, NC, Dr. Cromwell is a longtime thought leader in lipoprotein disorders and cardiovascular disease.

Learn more about Velocity's Cardiometabolic CARE Council: https://velocityclinical.com/cardiometabolic-care-council/

07/30/2025

Velocity’s ability to deliver at scale continues to improve speed and enrollment performance for trials worldwide.

For a recent trial, Velocity sites contributed over one-third of all participants, and outpaced other sites in screening, enrollment, and participants delivered per site.

Learn more about Velocity at Scale: velocityclinical.com/scale

07/28/2025

Site Selection Is Evolving — Are You Ready?

Join Paul Evans, President & CEO, for a forward-looking webinar: Site Selection Strategies in 2025: Leveraging Data-Driven Metrics for Success

Despite rapid advances in trial complexity and technology, site selection strategies haven’t kept pace. Most CROs and sponsors still rely on outdated feasibility surveys and static spreadsheets — missing out on high-performing sites ready to deliver today.

In this session, Paul and fellow experts will explore:

• Why traditional site selection methods fall short
• How real-world performance data is reshaping visibility and decision-making
• Practical steps to modernize site assessment and reduce costly delays
• What sites can do to stand out in a competitive market

At Velocity, we believe smarter data leads to smarter trials. Let’s rethink how we connect the right sites to the right studies — faster.

Register now to learn how data-driven strategies can transform trial efficiency and outcomes in 2025: https://xtalks.com/webinars/site-selection-strategies-in-2025-leveraging-data-driven-metrics-for-success/

07/17/2025

Today we announced our strategic partnership with Palantir Technologies, bringing cutting-edge AI to one of the clinical trial industry’s most frustrating pain points: payment reconciliation.

The announcement follows the news that Velocity is a founding member of Advarra's AI council and already deploys GenAI on its patient recruitment and engagement app, VISION, to match its database of more than 1.5 million participants with prospective studies.

Reconciling invoices and payments has traditionally been a fragmented, manual, and time-consuming process. During the pilot with Palantir's agentic AI solution, we processed and reconciled a massive volume of data, which would’ve taken our finance team more than nine months to complete manually. Now, we’re exploring how intelligent automation can streamline other operational areas; always with human expertise in the loop.

As our CTO, Raghu Punnamraju puts it: “Automating the AR reconciliation process is a game-changer. Our partnership with Palantir enables our teams to focus on what really matters — strategic growth and patient outcomes.

Read more: https://apnews.com/press-release/globenewswire-mobile/velocity-clinical-research-partners-with-palantir-to-solve-clinical-trials-payment-headache-7317c7354076e06ccdb06c867c670a52

07/16/2025

We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio.

This recognition is a testament to the dedication of our teams around the world who work every day to ensure clinical trial participants are supported, engaged, and enrolled with care and efficiency.

We’re honored to partner with AstraZeneca in advancing innovative therapies — and even more proud to play a leading role in getting those therapies to the patients who need them most.

07/14/2025

Heart disease is the leading cause of death worldwide. The increasing number of older individuals and the influence of patient lifestyle factors present challenges for the design, recruitment, and retention of participants in cardiovascular studies.

To address these issues, Velocity’s Cardiometabolic Council to Accelerate Research Excellence (CARE) provides high-impact strategies for operational efficiency, participant recruitment, and trial ex*****on at Velocity sites specializing in cardiology, metabolic, and related clinical research. The Cardiometabolic CARE Council, guided by physicians with extensive medical practice and research experience, provides real-world disease knowledge to the more than 40 Velocity sites conducting cardiology and cardiometabolic research.

Learn more about our CARE Council leaders: https://velocityclinical.com/cardiometabolic-care-council/

07/10/2025

Velocity taps into the expertise of our leading Principal Investigators and CARE Council members to review protocols. Internally, their feedback helps assess trials, align resources effectively. Externally, PI feedback has influenced study design.

Collectively, our reviewers have overseen the conduct of thousands of trials at the site level. They also offer extensive specialty practice experience, which informs real-world patient recruitment and retention strategies.
Whether it's at a Sponsor's request, or to support feasibility and site selection processes, Velocity has therapeutically specialized teams to review protocols within 48 hours.
Learn more about Velocity uniquely integrated approach to accelerating trials at scale: https://velocityclinical.com/capabilities/

Address

300 E. Main Street , Suite 300
Durham, NC
27701

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+19199261804

Website

https://velocityclinical.com/

Alerts

Be the first to know and let us send you an email when Velocity Clinical Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Durham?